Welcome to MyElanco Ireland!

The MyElanco Ireland website is intended for veterinary professionals and prescribers of animal health products. By continuing to MyElanco you are confirming your professional status as one of the above. 


Back to normal

Zenrelia (Ilunocitinib) gets nearly 50% more itchy dogs back to normal than Apoquel® (Oclacitinib)1††

Zenrelia once daily dosing

Once-daily dosing

Simple, consistent dosing from the start2

Itch control

Zenrelia delivers 24-hour itch relief1,3

Safety profile

Safety profile comparable to Apoquel1

Value

Zenrelia’s price helps make the benefits of JAK inhibitors for long-term itch relief accessible to more dogs‡

†† 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2)1

Based on list price of Zenrelia as of 07/25 vs other licensed JAK inhibitors for dogs.

  1. Forster S et al. Vet Dermatol. 2025 Apr;36(2):165-176
  2. Zenrelia™ Summary of Product Characteristics.
  3. Unpublished data: Owner Pruritus Assessment (PVAS) form.

Connect with Elanco

PM-IE-25-0130

2025 julí

© 2025 Elanco or its affiliates.